Relief Therapeutics Holding AG (RLFTF)

[SF Wolf]

Highly significant milestone.

This is the ACTIV-3 study funded by the NIH and is a randomized, blinded, placebo-controlled trial testing ZYESAMI and the antiviral remdesivir in hospitalized patients with acute respiratory failure due to COVID-19 who require high-flow supplemental oxygen, delivered by nasal cannula, mechanical ventilation, or extracorporeal membrane oxygenation.